Diagnostik und operative Therapie des Gastrinoms, Vipoms, Glukagonoms, Somatostatinoms und nichtfunktioneller endokriner Pankreastumoren

Zusammenfassung

Die einzige Möglichkeit, Patienten mit neuroendokrinen Pankreastumoren (NPTs) dauerhaft zu heilen, besteht in der kompletten chirurgischen Entfernung des Primarius, aber auch von Rezidiven und eventuell vorhandener Lymphknoten- oder Fernmetastasen. Dieser Grundsatz gilt sowohl für Gastrinome, Vipome, Glukagonome, Somatostatinome als auch die nicht-funktionellen NPTs. Durch einen aggressiven chirurgischen Therapieansatz kann neben einer dauerhaften Heilung von Patienten mit benignen NPTs ein Langzeitüberleben bei Patienten mit malignen NPTs erzielt werden.

Abstract

The only chance of cure for patients with pancreatic endocrine tumours (PETs) is complete surgical removal not only of the primary tumour, but also of local or distant metastases. This is true for gastrinomas, vipomas, glucagonomas, somatostatinomas and non-functional pancreatic endocrine tumours. An aggressive surgical approach leads to cure in patients with benign tumours, and may achieve long-term survival in patients with malignant NPTs.

Pankreastumor - endokrine Chirurgie - Pankreaschirurgie

pancreatic tumours - endocrine surgery - pancreatic surgery

Literatur

• 1 Öberg K, Eriksson B. Endocrine tumors of the pancreas.  Best Pract Res Clin Gastroenterol. 2005;  19 753-781
• 2 Fendrich V, Habbe N, Celik I et al. Operative Therapie und Langzeitüberleben bei neuroendokrinen Pankreastumoren Erfahrungen bei 144 Patienten.  Dtsch Med Wochenschr. 2007;  13 195-200
• 3 Bartsch D K, Schilling T, Ramaswamy A et al. Management of nonfunctioning islet cell carcinomas.  World J Surg. 2000;  24 1418-1424
• 4 Fendrich V, Bartsch D K, Langer P et al. Zollinger-Ellison-Syndrom – Das gewandelte Verständnis der Chirurgie.  Chirurg. 2005;  76 217-226
• 5 Yu F, Venzon D J, Serrano J et al. Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome.  J Clin Oncol. 1999;  17 615-630
• 6 Weber H C, Venzon D J, Lin T J et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: A prospective long-term study.  Gastroenterology. 1995;  108 1637-1649
• 7 Metz D C, Jensen R T. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors.  Gastroenterology. 2008;  135 1469-1492
• 8 Roy P K, Venzon D J, Shojamanesh H et al. Zollinger-Ellison syndrome. Clinical presentation in 261 patients.  Medicine. 2000;  79 379-411
• 9 Jensen R T, Gardner J D. Gastrinoma. In: Go VLW, Di Magno EP, Gardner JD, eds. The Pancreas: Biology, Pathobiology and Disease, 2nd ed. New York: Raven Press; 1993: 931
• 10 Dhillo W S, Jayasena C N, Lewis C J et al. Plasma gastrin measurement cannot be used to diagnose a gastrinoma in patients on either proton pump inhibitors or histamine type-2 receptor antagonists.  Ann Clin Biochem. 2006;  43 153-155
• 11 Berna M J, Hoffmann K M, Long S H et al. Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features.  Medicine (Baltimore). 2006;  85 331-364
• 12 Norton J A, Cornelius M J, Doppman J L et al. Effect of parathyroidectomy in patients with hyperparathyroidism, Zollinger-Ellison syndrome, and multiple endocrine neoplasia type I: a prospective study.  Surgery. 1987;  102 958-966
• 13 Frucht H, Howard J M, Slaff J et al. Secretin and calcium provocative tests in the Zollinger-Ellison syndrome. A prospective study.  Ann Intl Med. 1989;  111 713-722
• 14 Wada M, Komoto I, Doi R et al. Intravenous calcium injection test is a novel complementary procedure in differential diagnosis for gastrinoma.  World J Surg. 2002;  26 1291-1296
• 15 Kouvaraki M A, Solorzano C C, Shapiro S E et al. Surgical treatment of non-functioning pancreatic islet cell tumors.  J Surg Oncol. 2005;  89 170-185
• 16 Bajetta E, Ferrari L, Martinetti A et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors.  Cancer. 1999;  86 858-865
• 17 Langer P, Wild A, Hall A et al. Prevalence of multiple endocrine neoplasia type 1 in young patients with apparently sporadic primary hyperparathyroidism or pancreaticoduodenal endocrine tumours.  Br J Surg. 2003;  90 1599-1603
• 18 Stabile B E, Morrow D J, Passaro E. The gastrinoma triangle: Operative implications.  Am J Surg. 1984;  147 25-31
• 19 Sugg S L, Norton J A, Fraker D L et al. A prospective study of intraoperative methods to find and resect duodenal gastrinomas.  Ann Surg. 1993;  218 138-144
• 20 Zogakis T G, Gibril F, Libutti S K et al. Management and outcome of patients with sporadic gastrinoma arising in the duodenum.  Ann Surg. 2003;  238 42-48
• 21 Norton J A, Fraker D L, Alexander H R et al. Surgery to cure the Zollinger-Ellison syndrome.  N Engl J Med. 1999;  341 635-644
• 22 Zimmer T, Scherübl H, Faiss S et al. Endoscopic ultrasonography of neuroendocrine tumors.  Digestion. 2000;  62 Suppl 1 45-50
• 23 Anderson M A, Carpenter S, Thompson N W et al. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas.  Am J Gastroenterol. 2000;  95 2271-2277
• 24 Rothmund M, Angelini L, Brunt M et al. Surgery for benign insulinoma: an international review.  World J Surg. 1990;  14 393-399
• 25 Norton J A, Jensen R T. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome.  Ann Surg. 2004;  240 757-773
• 26 Noone T C, Hosey J, Firat Z et al. Imaging and localization of islet-cell tumors of the pancreas on CT and MRI.  Best Pract Res Clin Endocrinol Metab. 2005;  2 195-211
• 27 Virgolini I, Traub-Weidinger T, Decristoforo C. Nuclear medicine in the detection and management of pancreatic islet-cell tumors.  Best Pract Res Clin Endocrinol Metab. 2005;  2 213-227
• 28 Skogseid B, Oberg K, Akerstrom G et al. Limited tumor involvement found at multiple endocrine neoplasia type I pancreatic exploration: can it be predicted by preoperative tumor localization?.  World J Surg. 1998;  22 673-677
• 29 Langer P, Kann P H, Fendrich V et al. Prospective Evaluation of Imaging Procedures for the Detection of Pancreaticoduodenal Endocrine Tumors in Patients with Multiple Endocrine Neoplasia Type 1.  World J Surg. 2004;  28 1317-1322
• 30 Norton J A, Fraker D L, Alexander H R et al. Surgery increases survival in patients with gastrinoma.  Ann Surg. 2006;  244 410-419
• 31 Fendrich V, Langer P, Waldmann J et al. The management of sporadic and von Hippel endocrine neoplasia type 1 gastrinomas.  Br J Surg. 2007;  94 1331-1341
• 32 Anlauf M, Enosawa T, Henopp T et al. Primary lymph node gastrinoma or occult duodenal microgastrinoma with lymph node metastases in a MEN1 patient: the need for a systematic search for the primary tumor.  Am J Surg Pathol. 2008;  32 1101-1105
• 33 Mignon M, Ruszniewski P, Podevin P et al. Current approach to the management of a gastrinoma and insulinoma in adults with multiple endocrine neoplasia I.  World J Surg. 1993;  17 489-495
• 34 Fendrich V, Waldmann J, Bartsch D K et al. Surgical management of pancreatic endocrine tumors.  Nat Rev Clin Oncol. 2009;  6 419-428
• 35 Skogseid B, Oberg K, Akerstrom G et al. Limited tumor involvement found at multiple endocrine neoplasia type I pancreatic exploration: can it be predicted by preoperative tumor localization?.  World J Surg. 1998;  22 673-670
• 36 Thompson N W. Management of pancreatic endocrine tumors in patients with multiple endocrine neoplasia type 1.  Surg Clin N Am. 1998;  7 881-891
• 37 Bartsch D K, Fendrich V, Langer P et al. Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1.  Ann Surg. 2005;  242 757-764 ,  discussion 764–766
• 38 Tonelli F, Fratini G, Nesi G et al. Pancreatectomy in multiple endocrine neoplasia type 1-related gastrinomas and pancreatic endocrine neoplasias.  Ann Surg. 2006;  244 61-70
• 39 Imamura M, Komoto I, Doi R et al. New pancreas-preserving total duodenectomy technique.  World J Surg. 2005;  29 203-207
• 40 El Rassi Z S, Ferdinand L, Mohsine R M et al. Primary and second endocrine liver tumors: clinical presentation, surgical approach and outcome.  Hepatogastroenterology. 2002;  49 1340-1346
• 41 Lo C Y, van Heerden J A, Thompson G B et al. Islet cell carcinomas of the pancreas.  World J Surg. 1996;  20 878-884
• 42 Solorzano C C, Lee J E, Pisters P TW et al. Nonfunctioning islet cell carcinoma of the pancreas: Survival results in a contemporary series of 163 patients.  Surgery. 2001;  130 1078-1085
• 43 Fendrich V, Langer P, Celik I et al. An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors.  Ann Surg. 2006;  244 845-851 ,  discussion 852–853
• 44 Tran K T, Smeenk H G, van Eijck C HJ et al. Pylorus preserving pancreaticoduodenectomy versus standard Whipple procedure. A prospective, randomized, multicenter analysis of 170 patients with pancreatic and periampullary tumors.  Ann Surg. 2004;  240 738-745
• 45 Lowney J K, Frisella M M, Lairmore T C et al. Pancreatic islet cell tumor metastasis in multiple endocrine neoplasia type 1: correlation with primary tumor size.  Surgery. 1999;  125 1043-1049
• 46 Akerstrom G, Hessman O, Skogseid B. Timing and extent of surgery in symptomatic and asymptomatic neuroendocrine tumors of the pancreas in MEN1.  Langenbecks Arch Surg. 2002;  386 558-569
• 47 Fernandez-Cruz L, Cesar-Borges G. Laparoscopic strategies for resection of insulinomas.  J Gastrointest Surg. 2006;  10 752-760
• 48 Carrere N, Abid S, Julio C H et al. Spleen-preserving distal pancreatectomy with excision of splenic artery and vein: a case-matched comparison with conventional distal pancreatectomy with splenectomy.  World J Surg. 2007;  31 375-382
• 49 Hesse U. Die laparoskopische Pankreasresektion.  Zentralbl Chir. 2006;  131 162-166
• 50 Bärlehner E, Anders S, Schwetling R. Die laparoskopische Pankreaslinksresektion bei Tumoren.  Zentralbl Chir. 2001;  126 482-485